Patients younger than 40 years old and older than 70 years old affected by ER(−)/PR(−)/HER2(−) breast cancer have low survival rates: Results of a mono-institutional retrospective analysis

In our study, patients younger than 40 years old and older than 70 years affected by ER(−)/PR(−)/HER2(−) breast cancer have lower survival. Considering that there is no common behavior on how to treat older patients affected by this particular breast cancer phenotype, there is an increasing need to enroll older patients in clinical trials in order to realize tailored standards of care.